98 completed, 76 recruiting, 55 unknown, 34 terminated. 100 Phase 2, 71 Phase 1, 52 Phase 3, 32 Not applicable, 29 Phase 4.
Follow Lupus Nephritis: new trials by email Literature Review of Lupus Nephritis trials Research Report on Lupus Nephritis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy, in Patients With Refractory Systemic Lupus Erythematosus (GALLOP) CB-010 - Systemic Lupus Erythematosus, Lupus | Phase 1 | Withdrawn | Caribou Biosciences, Inc. | 2027-12-01 | 2025-09-19 | |
| A Study of BMS-986553 in Participants With Refractory Autoimmune Diseases BMS-986553 - Systemic Lupus Erythematosus, Sjögren's Disease | Phase 1 | Not yet recruiting | Bristol-Myers Squibb | 60 | 2026-10-30 | 2026-10-14 |
| Lupus Nephritis Care Pathway Lupus Nephritis (LN) Care Pathway - Lupus Nephritis (LN) | Not applicable | Recruiting | Duke University | 25 | 2026-10-14 | 2026-10-19 |
| Serum MPO-DNA Complexes as a Biomarker of Disease Activity in Systemic Lupus Erythematosus Systemic Lupus Erythematosus, Lupus Nephritis | Not yet recruiting | Assiut University | 90 | 2026-10-01 | 2026-09-08 | |
| BAFF CAR-T Cells (LMY-922) for Treatment of Refractory Autoimmune Disease LMY-922 - Rheumatoid Arthritis (RA), Systemic Lupus Erthematosus (SLE) | Phase 1 | Not yet recruiting | Luminary Therapeutics | 94 | 2026-10-01 | 2026-07-28 |
| CD19-Directed CAR-T Cell Therapy in Refractory Systemic Lupus Erythematosus Autologous CD19-Directed CAR-T Cells Manufactured at Ribeirão Preto Blood Center - Lupus Erythematosus, Systemic | Phase 1 / Phase 2 | Not yet recruiting | University of Sao Paulo | 16 | 2026-10-01 | 2026-06-22 |
| The Relation Between Serum Zinc and Lupus Nephritis Lupus Nephritis | Not yet recruiting | Assiut University | 75 | 2026-10-01 | 2026-01-02 | |
| C-CAR168, an Autologous Anti-CD20/BCMA Chimeric Antigen Receptor T-Cell Therapy, in Participants With Lupus Nephritis Refractory to Standard Therapy C-CAR168 - Lupus Nephritis (LN), Systemic Lupus Erythematosus (SLE) | Phase 2 | Not yet recruiting | AbelZeta Inc. | 50 | 2026-09-30 | 2026-10-13 |
| Clinical Utility of Serum Ribonuclease 1(RNASE1) as a Biomarker of Lupus Nephritis. System Lupus Erythematosus(SLE) | Not yet recruiting | Assiut University | 128 | 2026-09-30 | 2026-08-13 | |
| Study to Evaluate the Safety and Preliminary Efficacy of CD19 CAR-T Cell Therapy (TranspoCART19) in Patients With Refractory Lupus Nephritis TranspoCART19 - Lupus Nephritis, Lupus Nephritis (LN) | Phase 1 / Phase 2 | Recruiting | Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz | 10 | 2026-09-23 | 2026-10-01 |
| Diastolic Dysfunction and Inflammatory Biomarkers in Lupus Nephritis Lupus Nephritis, Diastolic Dysfunction | Not yet recruiting | Assiut University | 90 | 2026-09-20 | 2026-09-24 | |
| A Trial to Explore the Efficacy and Safety of O-triple as Initial Therapy in the Active Lupus Nephritis Patients (INITIAL Trial) obinutuzumab (RO5072759) - Lupus Nephritis | Phase 3 | Not yet recruiting | Zhao Minghui | 70 | 2026-09-10 | 2026-08-26 |
| Safety and Efficacy of ONT01 in Lupus ONT01 is a small molecule CD11b modulator. - Lupus Nephritis (LN), Lupus Nephritis - WHO Class III | Early Phase 1 | Recruiting | Hospital for Special Surgery, New York | 61 | 2026-09-04 | 2025-11-20 |
| Obinutuzumab for Systemic Lupus Erythematosus Pure Membranous Nephropathy: a Phase II Trial Obinutuzumab - Lupus Nephritis, Membranous Nephropathy | Phase 2 | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 65 | 2026-09-02 | 2026-07-23 |
| Neutrophil Extracellular Traps and Lupus Nephritis Serum Neutrophil Extracellular Traps - Lupus Nephritis (LN) | Not yet recruiting | Assiut University | 100 | 2026-09-01 | 2026-07-23 | |
| A Phase IIa Study of ICG318 CAR-T in Refractory Systemic Lupus Erythematosus With or Without Lupus Nephritis ICG318, BCMA-CD19-IL-15/IL-15 sushi Compound CAR T following lymphodepletion - Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN) | Phase 2 | Recruiting | iCell Gene Therapeutics | 20 | 2026-09-01 | 2026-09-17 |
| Predictors of ICU Admission and In-Hospital Mortality in Hospitalized Patients With Lupus Nephritis: The Prognostic Value of Neutrophil-to-Lymphocyte Ratio and C Reactive Protein to Serum Albumin Ratio Lupus Nephritis (LN) | Not yet recruiting | Khaled Samir Malak Nashed | 55 | 2026-09-01 | 2026-08-26 | |
| SII and SIRI as Prognostic Biomarkers in Lupus Nephritis Lupus Nephritis, Systemic Lupus Erythematosus | Not yet recruiting | Assiut University | 100 | 2026-08-19 | 2026-08-24 | |
| A Phase 2 Study to Evaluate the Safety, PD, PK, and Clinical Activity of ADX-097 in Participants With IgAN, LN or C3G ADX-097 - IgA Nephropathy, Lupus Nephritis (LN) | Phase 2 | Recruiting | Akebia Therapeutics | 30 | 2026-07-30 | 2026-10-01 |
| A Phase 2, Open-Label, Single-Arm Trial of FT819 in Participants With Lupus Nephritis FT819 - Lupus Nephritis, Systemic Lupus Erythematosus | Phase 2 | Recruiting | Fate Therapeutics | 53 | 2026-07-27 | 2026-09-14 |
Showing 20 of 331. Sign in to see all of them.
Lupus Erythematosus, Systemic (119) · Autoimmune Diseases (25) · Nephritis (18) · Scleroderma, Systemic (18) · Glomerulonephritis (14) · Myositis (14) · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (12) · Glomerulonephritis, IGA (11) · Proteinuria (10) · Glomerulonephritis, Membranous (9) · Kidney Diseases (8) · Scleroderma, Diffuse (8) · Renal Insufficiency, Chronic (7) · Dermatomyositis (6)
Female Urogenital Diseases (331) · Female Urogenital Diseases and Pregnancy Complications (331) · Male Urogenital Diseases (331) · Skin and Connective Tissue Diseases (331) · Urogenital Diseases (331) · Connective Tissue Diseases (330) · Urologic Diseases (330) · Immune System Diseases (329) · Kidney Diseases (323) · Glomerulonephritis (317) · Nephritis (313) · Autoimmune Diseases (306) · Lupus Erythematosus, Systemic (212) · Pathological Conditions, Signs and Symptoms (29) · Skin Diseases (28)
Mycophenolic Acid (45) · Cyclophosphamide (43) · Tacrolimus (17) · fludarabine (17) · Prednisone (16) · Azathioprine (13) · Rituximab (12) · Adrenal Cortex Hormones (11) · voclosporin (11) · Prednisolone (10) · Methylprednisolone (8) · belimumab (7) · obinutuzumab (7) · dapagliflozin (6) · Acetaminophen (5)
Assiut University (21) · Novartis Pharmaceuticals (10) · Aurinia Pharmaceuticals Inc. (8) · Nanjing University School of Medicine (8) · Hoffmann-La Roche (7) · National Institute of Allergy and Infectious Diseases (NIAID) (5) · RenJi Hospital (5) · Sun Yat-sen University (5) · The University of Hong Kong (5) · Ain Shams University (4) · Beijing GoBroad Hospital (4) · Bristol-Myers Squibb (4) · China Immunotech (Beijing) Biotechnology Co., Ltd. (4) · Chulalongkorn University (4) · Genentech, Inc. (4)
United States (113) · China (93) · Spain (40) · France (33) · Germany (32) · Mexico (32) · South Korea (30) · Brazil (27) · Argentina (25) · Australia (24) · United Kingdom (24) · Italy (23) · Taiwan (23) · Thailand (23) · Poland (21)
David Wofsy, MD (3) · Anca D Askanase, MD, MPH (2) · Betty Diamond, M.D. (2) · Betty Diamond, MD (2) · Cheuk-Chun Szeto, MD (2) · David Wofsy, M.D. (2)
PMID 37528520, PMID 33693991, PMID 22087680, PMID 29450636, PMID 38334499, PMID 39673415, PMID 40465397, PMID 41092316, PMID 42175562, PMID 11511139, PMID 12209517, PMID 1356175, PMID 14989631, PMID 15807196, PMID 16881113, PMID 18596121, PMID 18668592, PMID 18686612, PMID 19369404, PMID 19933596, PMID 20039429, PMID 20414362, PMID 20605876, PMID 21080348, PMID 21177013, PMID 21356124, PMID 21943027, PMID 22231479, PMID 22325903, PMID 22566930, PMID 22922564, PMID 24396421, PMID 25031267, PMID 25334031, PMID 25383558, PMID 25403681, PMID 25550339, PMID 25757867, PMID 25779381, PMID 25927414, PMID 26629352, PMID 26835147, PMID 26867033, PMID 27110697, PMID 28143529, PMID 28478399, PMID 29045037, PMID 29212518, PMID 29515299, PMID 29669944
2023 (5), 2015 (2), 2018 (2), 2019 (2), 2025 (2), 2014 (1), 2017 (1), R01AR079124 (1)